Stockscreener 앱 받기
11.45
0.35%
-0.04
시간 외 거래:
11.33
-0.12
-1.05%
전일 마감가:
$11.49
열려 있는:
$11.62
하루 거래량:
1.94M
Relative Volume:
1.40
시가총액:
$709.72M
수익:
-
순이익/손실:
$-148.00M
주가수익비율:
-2.5847
EPS:
-4.4299
순현금흐름:
$-135.66M
1주 성능:
+3.15%
1개월 성능:
+70.90%
6개월 성능:
+88.01%
1년 성능:
+0.00%
1일 변동 폭
$11.38
$11.95
1주일 범위
$9.835
$11.95
52주 변동 폭
$3.76
$11.95
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
11.45 | 712.20M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | TD Cowen | Buy |
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Helus Pharma Inc 주식(HELP)의 최신 뉴스
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Canada
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - Stock Titan
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat - Stock Titan
Cybin’s Helus Pharma to join Canaccord Genuity Annual Growth Conference fireside chat - Bitget
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in BostonMon, 08/10/202612:00 - Helus Pharma
Cybin (HELP) Names New CEO, Is The Stock Still Cheap? - Yahoo! Finance Canada
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed? - Yahoo Finance
Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data - kalkine.ca
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale? - simplywall.st
Helus Pharma Shares Rise After Appointing New CEO - Moomoo
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout - The Manila Times
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies ... - Caledonian Record
A CEO With a Proven Track Record of Success in Growing and - GlobeNewswire
Helus Pharma appoints Michael Halstead as chief executive - Investing.com
Helus Pharma Appoints Michael Halstead as Chief Executive Officer - The Manila Times
Helus Pharma appoints Michael Halstead as chief executive By Investing.com - Investing.com India
Helus Pharma (HELP.NE) Names Michael Halstead CEO Ahead of Phase 3 HLP003 Data Readout - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - tradingview.com
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweight - GuruFocus
Helus Pharma Price Target Announced at $16.00/Share by Wells Fargo - Moomoo
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions - Yahoo Finance
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
Cybin D/B/A Helus Pharma (HELP.NE) stock price, news, quote and history - Yahoo Finance UK
HELP: Helus Pharma Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Helus Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada
Helus Pharma Inc. (HELP) News, Articles, Events & Latest Updates - Stocktwits
Helus Pharma (HELP) Achieves Enrollment Milestone in Phase 3 Stu - GuruFocus
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs - Yahoo Finance
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of H - GuruFocus
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule - Nasdaq
Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com - Investing.com Canada
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Cantech Letter
Helus Pharma completes enrollment in Phase 3 tr... - Pluang
Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin - simplywall.st
Cybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters? - simplywall.st
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Finansavisen
Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million - Yahoo Finance
Helus Pharma (Nasdaq: HELP) closes US$50M underwritten share offering - Stock Titan
Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results? - Yahoo Finance
Helus Pharma Inc (HELP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.33%
자본화:
|
볼륨(24시간):